Recent research has found that “first-line therapy with zidovudine and interferon-alpha improved overall survival with adult T-cell leukemia/lymphoma (ATL) in a retrospective study – but the benefit was limited to patients with the leukemic subtypes.” This has to be somewhat good news for those suffering from leukemia/lymphoma. Nonetheless, there is still much work to be done. And that is why it is essential that people who care support such organizations like the Leukemia and Lymphoma Society (LLS), as does businessman Corey Ribotsky.
Recent Posts
Archives
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
Categories
- Asian Investment
- charity work
- Children's Medical Fund
- CMFNY
- Corey Ribotsky
- Cyberlux
- General Motors
- Heather on Earth
- Hedge Funds
- Hedge Funds for Habitat
- Investment Funds
- Leukemia and Lymphoma Society
- music therapy
- NIR Group
- North Shore-LIJ Health System
- NY Times
- Onyx and Breezy Foundation
- PIPE Deals
- Press
- Ribotsky
- Shoham Cohen
- Sunrise Day Camp
Recent Comments